Drug intelligence / Profile preview

kynurenic acid amide

Development stage: Preclinical
Modality: Small Molecules
Administration: Systemic

Overview

Kynurenic acid amide (KYNAa) is a newly synthesized derivative of kynurenic acid, designed to improve blood-brain barrier penetration. It acts as a glutamate receptor antagonist and inhibits α7-nicotinic acetylcholine receptors. This small molecule is being investigated for its potential therapeutic use in migraine headache, where it has shown to modulate neurochemical markers of activation and sensitization of the trigeminal system in preclinical models.

Other names: N-(2-N-pyrrolidinylethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride

Targets

CHRNA7 (α7 nicotinic receptor)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on kynurenic acid amide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on kynurenic acid amide.

Explore the full profile